FDA approves grape-flavored Delsym
This article was originally published in The Tan Sheet
Executive Summary
FDA approved Adams Respiratory Therapeutics supplemental New Drug Application for a grape-flavored formulation for Delsym on Sept. 28 and the company will begin immediately distributing the cough medicine product, Chester, N.J.-based Adams says. Upon acquiring Delsym from USB in May 2006, the firm said it would pour $15 mil-$20 mil. annually into distribution and promotions (1"The Tan Sheet" May 29, 2006, p. 5)...
You may also be interested in...
Adams Expands OTC Cough Market Presence With Delsym Acquisition
Adams Respiratory Therapeutics intends to aggressively promote Delsym cough suppressant to consumers following its May 24 acquisition of the brand
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.